title: NICE backs leukaemia drug after manufacturer drops price.
authors.forename: Jacqui
authors.initials: J
authors.lastname: Wise
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001549:Benzamides; D003362:Cost-Benefit Analysis; D000069439:Dasatinib; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000191:economics*; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib